TCGA-CV-5976-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.530
- NOTCH_SIGNALING+0.300
- HEDGEHOG_SIGNALING+0.290
- APICAL_JUNCTION+0.260
- TGF_BETA_SIGNALING+0.220
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- HYPOXIA+0.180
- ANGIOGENESIS+0.150
- P53_PATHWAY+0.150
- UV_RESPONSE_DN+0.150
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.320
- IL6_JAK_STAT3_SIGNALING-0.320
- INTERFERON_GAMMA_RESPONSE-0.280
- E2F_TARGETS-0.240
- G2M_CHECKPOINT-0.200
- PANCREAS_BETA_CELLS-0.160
- INFLAMMATORY_RESPONSE-0.140
- IL2_STAT5_SIGNALING-0.120
- PI3K_AKT_MTOR_SIGNALING-0.120
- COMPLEMENT-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208959 | — | — | 0.768 |
| 2 | GSM5359429 | — | — | 0.730 |
| 3 | TCGA-BH-A0H6-01A-21R-A056-07 | — | A | 0.717 |
| 4 | X9d79253b.8c45.4bde.a42d.c399fb107400 | — | cohortMD2 | 0.705 |
| 5 | SRR975596 | — | — | 0.692 |
| 6 | R302 | — | — | 0.691 |
| 7 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.679 |
| 8 | SRR2932825 | — | — | 0.673 |
| 9 | SRR8613703 | — | D | 0.670 |
| 10 | SRR11296891 | — | — | 0.669 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.530 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |